Elsevier

Human Immunology

Volume 80, Issue 6, June 2019, Pages 351-362
Human Immunology

Primary B-cell immunodeficiencies

https://doi.org/10.1016/j.humimm.2018.10.015Get rights and content

Abstract

Primary B-cell immunodeficiencies refer to diseases resulting from impaired antibody production due to either molecular defects intrinsic to B-cells or a failure of interaction between B-cells and T-cells. Patients typically have recurrent infections and can vary with presentation and complications depending upon where the defect has occurred in B-cell development or the degree of functional impairment. In this review, we describe B-cell specific immune defects categorized by presence or absence of peripheral B-cells, immunoglobulins isotypes and evidence of antibody impairment.

Introduction

About 20% of serum proteins are immunoglobulins, containing all the antibody species that a human needs for protection against most infections [1]. Functional antibodies are the end product of multiple steps that include continuous reconfiguration of genes for the B-cell antigen receptors (BCR) along with the elimination of perhaps 90% of poly-reactive and autoreactive B-cells during this process [2]. One of the most illuminating lessons about B-cell biology has arisen from studies of the primary immune defects that prevent normal B-cell development. While more than 300 primary immune defects are now known [3], clinically, the most common defects found in patient populations are those that impair B-cell development or function (Fig. 1).

B-cell immunodeficiencies are often distinguished from other immune defects, by age of onset, clinical parameters, severity and mode of inheritance. The types of infections that hallmark an underlying B-cell defect include recurrent infections that are typically encapsulated bacteria, distinct from patients with T-cell or combined immunodeficiencies, who are more likely to have opportunistic or severe viral or infections. B-cell defects are quite heterogeneous, and include loss of immune globulins, and/or impaired antibody production. These result from molecular defects intrinsic to B-cells, failure of required interactions between B- and T-cells, loss of appropriate bone marrow or germinal center responses, and defects of immune regulation. These defects result in a variable loss of B-cells, reduction or absence of serum immunoglobulins and/or loss of antibody function. B-cell immunodeficiencies are categorized into the following: 1) a severe reduction in all serum immunoglobulin isotypes with profoundly decreased or absent B cells, recognized as agammaglobulinemia; 2) severe reduction in at least 2 serum immunoglobulin isotypes (typically IgG and IgA) with normal or low number of B cells (CVID phenotype); 3) severe reduction in serum IgG and IgA with normal/elevated IgM with normal numbers of B cells (Hyper IgM syndrome); 4) Isotype or light chain deficiencies with generally normal numbers of B cells (these are outlined in Table 1).

Section snippets

X-linked agammaglobulinemia (XLA)

Agammaglobulinemia is characterized by absence of circulating B-cells with severe reduction in all serum immunoglobulin levels. Clinically, this is a rare defect (1:100,000 to 1:200,000 depending on ethnicity and the specific genetic defect) [4]. Both X-linked and autosomal recessive forms of the disease have been described. The classic disorder of B-cell development is X-linked agammaglobulinemia (XLA), first described in 1952 by Ogden Bruton, who reported an eight-year-old boy with recurrent

Common variable immune deficiency (CVID)

After early B-cell development with successful generation of cells bearing a functional BCR, B-cells move from the bone marrow to the spleen and peripheral lymphoid tissues, where additional maturational events occur which lead to plasma cell development. Failing any of these steps results in varying degrees of hypogammaglobulinemia. From the clinical point of view, patients are usually given the generic label, common variable immune deficiency (CVID). One of the essential issues in CVID is

Hyper IgM syndrome: severe reduction in serum IgG and IgA with normal/elevated IgM and normal B-cell numbers.

Class-switch recombination (CSR) occurs downstream of T-cell dependent B-cell activation in germinal centers. Activated follicular B-cells receive help from cognate T follicular helper cells to undergo CSR and somatic hypermutation (SHM). Eventually, CSR and SHM result in high-affinity antibody production and the differentiation of B-cells into long-lived memory B-cells and plasma cells [71]. Immunoglobulin class switch recombination deficiencies, previously termed “hyper-IgM syndromes (HIGM)”

Selective IgA deficiency (SIGAD)

Selective IgA deficiency is the most common primary antibody deficiency, with worldwide incidence varying depending on the ethnic background (1:143 to 1:18,500) [86]. It affects males and females equally and is defined as a serum IgA level of less than 7 mg/dl and normal levels of serum IgG and IgM in a patient older than 4 years old [87]. Primary IgA deficiency must be distinguished from secondary causes due to medications such as anticonvulsants (phenytoin, carbamazepine, valproic acid),

Diagnosis

Diagnosing a primary B-cell defect relies first on clinical history and then on confirmatory laboratory evaluations. This includes a detailed family and infection history, age of onset, frequency and duration of treatments and if known, organisms that might suggest a primary B-cell defect or a combined B- and T-cell immune defect. Laboratory evaluations include complete blood counts, full lymphocyte panels for T-cell, B-cell, and NK-cell subsets, quantitative serum immunoglobulin levels (IgM,

Treatment

The management of primary B-cell immunodeficiencies focuses largely on the prevention and treatment of infections and secondarily on controlling any complications that may develop. Adequate antibody replacement therapy for those with documented loss of functional IgG is key, with intravenous or subcutaneous immune globulin formulations being the primary cornerstone in the care of patients. Microbial therapy is used as needed for acute treatment, and in some cases, chronic antibiotic

Conclusion

Murine models have illustrated the most basic principles of B-cell biology, but what is most solidly known for human B-cell immunity, has often been based on studies of primary immunodeficiencies (PID). X-linked agammaglobulinemia permitted the elucidation of cytoplasmic tyrosine kinase BTK, crucial for maturation of mature B-cells. Defects of all of the components of the BCR result in autosomal agammaglobulinemia, demonstrating that continuous BCR signals are essential for the maintenance of

Disclosure information

T. Smith and C. Cunningham-Rundles have no relevant conflicts of interest to disclose.

Acknowledgements

Funding for this study was provided by the National Institutes of Health grants, AI-061093, AI-086037, AI-48693, and David S. Gottesman Immunology Chair at the Icahn School of Medicine at Mount Sinai.

References (124)

  • M. Martinez-Gallo et al.

    TACI mutations and impaired B-cell function in subjects with CVID and healthy heterozygotes

    J. Allergy Clin. Immunol.

    (2013)
  • L. Zhang et al.

    Transmembrane activator and calcium-modulating cyclophilin ligand interactor mutations in common variable immunodeficiency: clinical and immunologic outcomes in heterozygotes

    J. Allergy Clin. Immunol.

    (2007)
  • K. Warnatz et al.

    Human ICOS deficiency abrogates the germinal center reaction and provides a monogenic model for common variable immunodeficiency

    Blood

    (2006)
  • J. Thiel et al.

    Genetic CD21 deficiency is associated with hypogammaglobulinemia

    J. Allergy Clin. Immunol.

    (2012)
  • J.M. van Montfrans et al.

    CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia

    J. Allergy Clin. Immunol.

    (2012)
  • G. Lopez-Herrera et al.

    Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity

    Am. J. Hum. Genet.

    (2012)
  • L. Gámez-Díaz et al.

    The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency

    J. Allergy Clin. Immunol.

    (2016)
  • T.I. Coulter et al.

    Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: a large patient cohort study

    J. Allergy Clin. Immunol.

    (2017)
  • E. Elkaim et al.

    Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: a cohort study

    J. Allergy Clin. Immunol.

    (2016)
  • K. Chen et al.

    Germline mutations in NFKB2 implicate the noncanonical NF-κB pathway in the pathogenesis of common variable immunodeficiency

    Am. J. Hum. Genet.

    (2013)
  • A. Durandy et al.

    Pathophysiology of B-cell intrinsic immunoglobulin class switch recombination deficiencies

    Adv. Immunol.

    (2007)
  • A. Aruffo et al.

    The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome

    Cell

    (1993)
  • J. Levy et al.

    Clinical spectrum of X-linked hyper-IgM syndrome

    J. Pediatr.

    (1997)
  • P. Revy et al.

    Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the hyper-IgM syndrome (HIGM2)

    Cell

    (2000)
  • Y. Minegishi et al.

    Mutations in activation-induced cytidine deaminase in patients with hyper IgM syndrome

    Clin. Immunol.

    (2000)
  • P. Quartier et al.

    Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to activation-induced cytidine deaminase deficiency

    Clin. Immunol.

    (2004)
  • F.A. Bonilla et al.

    Practice parameter for the diagnosis and management of primary immunodeficiency

    J. Allergy Clin. Immunol.

    (2015)
  • M. Janzi et al.

    Selective IgA deficiency in early life: association to infections and allergic diseases during childhood

    Clin. Immunol.

    (2009)
  • S. Agarwal et al.

    Diagnosis and treatment of gastrointestinal disorders in patients with primary immunodeficiency

    Clin. Gastroenterol. Hepatol.

    (2013)
  • K.W. Jacobson et al.

    Selective immunoglobulin A deficiency associated with nodular lymphoid hyperplasia

    J. Allergy Clin. Immunol. 64

    (1979)
  • M.F. Goldstein et al.

    Selective IgM immunodeficiency: retrospective analysis of 36 adult patients with review of the literature

    Ann. Allergy Asthma Immunol.

    (2006)
  • C. Picard et al.

    International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee report on inborn errors of immunity

    J. Clin. Immunol.

    (2018)
  • E.R.S.A. Plebani et al.

    Chapter 13 – agammaglobulinemia

  • O.C. Bruton

    Agammaglobulinemia

    Pediatrics

    (1952)
  • D. Gitlin et al.

    Agammaglobulinemiae

    Trans. Assoc. Am. Physicians

    (1953)
  • V. David et al.

    The gene involved in X-linked agammaglobulinaemia is a membe

    Nature

    (1993)
  • C.I. Smith et al.

    Expression of Bruton’s agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells

    J. Immunol.

    (1994)
  • J.A. Winkelstein et al.

    X-linked agammaglobulinemia: report on a United States registry of 201 patients

    Medicine (Baltimore)

    (2006)
  • M.E. Conley et al.

    Genetic analysis of patients with defects in early B-cell development

    Immunol. Rev.

    (2005)
  • R.A. Good et al.

    Hypoimmunoglobulinemia with normal T cell function in female siblings

    Clin. Immunol. Immunopathol.

    (1977)
  • L. Yel et al.

    Mutations in the Mu heavy-chain gene in patients with agammaglobulinemia

    N. Engl. J. Med.

    (1996)
  • E. Lopez Granados et al.

    Clinical and molecular analysis of patients with defects in μ heavy chain gene

    J. Clin. Invest.

    (2002)
  • M.E. Conley et al.

    Primary B cell immunodeficiencies: comparisons and contrasts

    Annu. Rev. Immunol.

    (2009)
  • F. Melchers et al.

    The surrogate light chain in B-cell development

    Immunol. Today

    (1993)
  • E4511D2F-7699-4FCA-94D1-F2F5463A6ADA,...
  • F. Papavasiliou et al.

    The role of Ig beta in precursor B cell transition and allelic exclusion

    Science (80–)

    (1995)
  • M. Reth

    Antigen receptors on B lymphocytes

    Annu. Rev. Immunol.

    (1992)
  • Y. Wang et al.

    Novel Igα (CD79a) gene mutation in a Turkish patient with B cell-deficient agammaglobulinemia

    Am. J. Med. Genet.

    (2002)
  • Y. Minegishi et al.

    An essential role for BLNK in human B cell development

    Science (80-)

    (1999)
  • M.E. Conley et al.

    Agammaglobulinemia and absent B lineage cells in a patient lacking the p85α subunit of PI3K

    J. Exp. Med.

    (2012)
  • Cited by (41)

    • NF-κB-inducing kinase maintains mitochondrial efficiency and systemic metabolic homeostasis

      2023, Biochimica et Biophysica Acta - Molecular Basis of Disease
    • COVID-19 in patients with B cell immune deficiency

      2022, Journal of Immunological Methods
    • Approach to the Evaluation of the Patient  With Suspected Immunodeficiency

      2022, Clinical Immunology: Principles and Practice, Sixth Edition
    View all citing articles on Scopus
    View full text